期刊文献+

颛桥社区老年高血压患者3种干预方式的直接成本-效用研究

Study of the direct cost utility of 3 intervention methods for elderly hypertensive patients in Zhuanqiao Community
下载PDF
导出
摘要 目的 :调查评价颛桥社区老年高血压患者接受不同干预方式的疾病直接成本效用。方法 :采用方便抽样方法于2017年10月选取老年高血压合并症患者148例,其中颛桥社区卫生服务中心接受住院治疗干预的患者58例、颛桥敬老院接受巡回医疗干预的患者30例,颛桥各社区接受"1+1+1"组合签约门诊干预的患者60例(进一步细分为门诊高龄亚组与门诊低龄亚组)。计算三组患者于2016年5月1日—2018年4月30日2年时间内接受不同干预方式的疾病直接成本—效用。结果 :2年的抗高血压药物费用为门诊高龄组最高(2 679.91元),门诊低龄组最低(2 210.43元);单纯计算抗高血压药物治疗费用,每获得一个完整QALY的成本为住院组最高(2 521.22元),门诊低龄组最低(1 627.50元);从总直接成本、自付总金额来看,总直接成本为住院组最高(179 143.29元),门诊低龄组最低(19 215.47元),三组患者每获得一个完整QALY的费用差异有统计学意义(P <0.001);自付总金额为住院组最高(63 574.97元),门诊低龄组最低(9 929.61元)。结论 :"1+1+1"组合签约服务和巡回医疗等医疗模式的开展极大地减轻了老年高血压患者的疾病经济负担,具有现实意义。 Objective: To investigate and evaluate the direct cost utility of different chronic diseases intervention methods for elderly patients with hypertension in Zhuanqiao Community. Methods: In October, 2017, 148 elderly patients with hypertension complication were selected by convenience sampling, among them, 58 cases of patients received hospitalization intervention in Zhuanqiao Community Health Service Center, 30 patients received itinerant medical intervention in the Nursing Home of Zhuanqiao, and 60 patients in Zhuanqiao Community received the “1+1+1” combined signing outpatient intervention(further subdivided into an outpatient senior subgroup and an outpatient junior subgroup). The direct cost utility of the patients in three groups receiving diferent interventions during the two years from May 1, 2016 to April 30, 2018 was calculated. Results: The cost of antihypertensive drugs for 2 years was the highest in the outpatient senior group(2 679.91 Yuan), and the lowest in the outpatient junior group(2 210.43 Yuan); the cost of antihypertensive medications was calculated simply and the cost of obtaining a complete QALY was the highest in the inpatient group(2 521.22 Yuan), and the lowest in the outpatient junior group(1 627.50 Yuan); in terms of total direct cost and total amount of self-payment, the total direct cost was the highest in the inpatient group(179 143.29 Yuan) and the lowest in the outpatient junior group(19 215.47 Yuan), and there was a statistically signifcant diference in the cost of obtaining a complete QALY between the three groups(P〈0.001); the total amount of self-payment was the highest in the inpatient group(63 574.97 Yuan), and the lowest in the outpatient junior group(9 929.61 Yuan). Conclusion: The “1+1+1” combined signing service and itinerant medical treatment modes have greatly reduced the economic burden of the elderly patients with hypertension, which is of practical signifcance.
作者 周梅花 朱宇霞 李丽秋 钱洁 徐丽燕 万育春 陈军香 ZHOU Meihua;ZHU Yuxia;LI Liqiu;QIAN Jie;XU Liyan;WAN Yuchun;CHEN Junxiang(Department of Nursing of Zhuanqiao Community Health Service Center of Minhang District,Shanghai 201108,China;Department of Pharmacy of Zhuanqiao Community Health Service Center of Minhang District,Shanghai 201108,China;Department of Medical Administration of Zhuanqiao Community Health Service Center of Minhang District,Shanghai 201108,China;Outpatient Department of General Practice of Zhuanqiao Community Health Service Center of Minhang District,Shanghai 201108,China;Department of Hospital Administration of Zhuanqiao Community Health Service Center of Minhang District,Shanghai 201108,China)
出处 《上海医药》 CAS 2018年第20期6-9,共4页 Shanghai Medical & Pharmaceutical Journal
基金 上海市闵行区自然科学研究课题(2017MHZ47)
关键词 “1+1+1”组合签约服务 住院治疗 巡回医疗 成本效用 “1+1+1” combined signing service inpatient treatment itinerant medical treatment cost utility
  • 相关文献

参考文献5

二级参考文献75

  • 1中国老龄科学研究中心课题组,张恺悌,孙陆军,牟新渝,王海涛,李明镇.全国城乡失能老年人状况研究[J].残疾人研究,2011(2):11-16. 被引量:307
  • 2郭东,李惠优,李绪贤,官计彬.医养结合服务老年人的可行性探讨[J].国际医药卫生导报,2005,11(21):43-44. 被引量:130
  • 3Hajj ar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United Statcs, 1988-2000.JAMA 2003,290(2) : 199-206.
  • 4Staessen JA, Gasowski J, Wang JG, et al . .. Risks of un- treated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355(9207), 865-72.
  • 5Fedder DO, Koro CE, L'Italien GJ: New National Cho- lesterol Edusation Program Ⅲ guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-el- igible population. Circulation 2002,105(2) : 152-6.
  • 6American diabetes Association.clinical practice remmen- dation. Diabetes Care 2002,25 ; S1-147.
  • 7Pearson TA, Laurora I, Chu H, KMonek S.. The lipid treatment assessment project (L-TAP) : a multicenter survey to evaluate the percentages of dyslipidemic pa- tients receiving lipid-lowering therapy and achieving low density lipoprotein cholesterol goals. Arch Intern Med 2000,160(4), 459-67.
  • 8EUROASP1RE. A European Society of Cardiology sur- vey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group, Europe- an Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997:1569-82.
  • 9Clinical reality of coronary prevention guidelines., a com- parison of EROASPLRE Ⅰ and Ⅱ in nine countries: EROASPIRE I and II Group. European Action on Sec- ondary Prevention by Intervention to Reduce Events. Lancet 2001,357 : 995-1001.
  • 10Bernard DB, Townsend RR, Sylvestri MF: Health and disease management: What is it and where is it going? What is the role of health and disease management in hypertension? Am JHypertens 1998,11 : 103-88.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部